{"disease":{"id":"metastatic-solid-tumours","name":"metastatic solid tumours"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04999969","title":"Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":126,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04839991","title":"Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Crescendo Biologics Ltd.","has_results":false},{"nct_id":"NCT05021120","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Akesobio Australia Pty Ltd","has_results":false},{"nct_id":"NCT02610075","title":"Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02285816","title":"MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":56,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT03548467","title":"A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Nykode Therapeutics ASA","has_results":false},{"nct_id":"NCT05836623","title":"A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":5,"lead_sponsor_name":"Crescendo Biologics Ltd.","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}